News
Public · Published
PolyPeptide Group: Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.
Samsung Biologics, through subsidiary Samsung Peptide AG, published the provisional result of its public offer for all publicly held PolyPeptide shares. After the additional acceptance period ended on 30 October 2026, Samsung Peptide and concert parties held 32,458,892 shares, or 97.99% of PolyPeptide's issued shares and voting rights.
Published:
Updated:
What happened
Samsung Biologics, through subsidiary Samsung Peptide AG, published the provisional result of its public offer for all publicly held PolyPeptide shares. After the additional acceptance period ended on 30 October 2026, Samsung Peptide and concert parties held 32,458,892 shares, or 97.99% of PolyPeptide’s issued shares and voting rights.
Confirmed
Global impact / market context
The reported 97.99% holding indicates that Samsung Biologics and its aligned parties would control nearly all of PolyPeptide’s shares and voting rights. That could reduce the shares available for public investors and give the group greater influence over the peptide producer’s strategic choices and spending.
Analyst inference
The article reports a provisional tender-offer result, not a completed final outcome or details of future ownership arrangements. The near-total reported holding suggests limited remaining public ownership, but the supplied text gives no offer price, financing terms, or expected financial effects on either company.
Analyst inference
What to watch
- Watch for the final tender-offer result and any confirmation of the eventual shareholding, since the published figure is explicitly provisional and may not be the final total. Analyst inference
- Check for announcements on how Samsung Biologics plans to manage PolyPeptide, including any changes to investment, operating costs, or commercial priorities; none are stated here. Analyst inference
- The additional acceptance period ended on 30 October 2026 at 4:00 p.m. Swiss time; Samsung Peptide reported that tendered shares represented 97.66% of PolyPeptide’s issued share capital and voting rights. Confirmed